Objective: Influenza and pneumococcal infections, cause life-threatening conditions in geriatric population by physiological changes and comorbid diseases. In our study, the pneumococcal/influenza vaccination status of the geriatric population hospitalized with the diagnosis of respiratory infections and their effects to the prognostic and demographic factors of the patients and the costs of hospitalization, were investigated. Material and Methods: Sociodemographic clinical findings and pneumococcal/influenza vaccination status of patients hospitalized with the diagnosis of non coronavirus disease-2019 respiratory tract infections between 1st January and 31th December 2022, were analyzed retrospectively. Results: A total of 944 patients were evaluated in our study. We determinated that 75.5% of all patients were discharged and 24.6% of patients died. It was determined that 12.3% of the patients had both pneumococcal and influenza vaccines, 9.7% were vaccinated only with influenza and 56.9% were not vaccinated with any vaccine. Pneumococcal and/or influenza protected patients were found to have significantly lower mortality rates and hospitalization costs compared to patients without vaccine protection (p<0.001). It was observed that single influenza vaccine protection was more effective and protective than single pneumococcal vaccine protection. Conclusion: Influenza vaccine addition to the routine vaccination program might significantly reduces the financial burden on the hospital/state for geriatric patients.
Keywords: Pneumococcal vaccination; hospitalization; health care cost
Amaç: İnfluenza ve pnömokokal enfeksiyonlar, fizyolojik değişiklikler ve eşlik eden hastalıklar ile geriatrik popülasyonda yaşamı tehdit eden durumlara neden olmaktadır. Çalışmamızda, solunum yolu enfeksiyonu tanısı ile hastaneye yatırılan geriatrik popülasyonun pnömokok/influenza aşılanma durumları, hastaların prognostik ve demografik faktörlerine ve yatış maliyetlerine etkileri araştırıldı. Gereç ve Yöntemler: 1 Ocak-31-Aralık 2022 tarihleri arasında koronavirüs hastalığı-2019 dışı solunum yolu enfeksiyonu tanısı ile yatırılan hastaların sosyodemografik özellikleri ile klinik bulguları ve pnömokok/influenza aşılama durumları retrospektif olarak incelendi. Bulgular: Çalışmamızda toplam 944 hasta değerlendirildi. Tüm hastaların %75,5?inin taburcu edildiği ve %24,6?sının eks olduğu belirlendi. Hastaların %12,3?ünün hem pnömokok hem de influenza aşısı yaptırdığı, %9,7?sinin sadece influenza ile aşılandığı ve %56,9?unun ise herhangi bir aşı ile aşılanmadığı tespit edildi. Pnömokok ve/veya influenza korumalı hastaların ölüm oranlarının ve hastanede yatış maliyetlerinin aşı koruması olmayan hastalara göre anlamlı olarak düşük olduğu saptandı (p<0,001). Tek influenza aşısı korumasının, tek pnömokok aşısına göre daha etkili ve koruyucu olduğu görüldü. Sonuç: Rutin aşılama programına grip aşısının eklenmesi, geriatrik hastalar için hastane/devlet üzerindeki mali yükü önemli ölçüde azaltabilir.
Anahtar Kelimeler: Pnömokok aşısı; hastaneye yatış; sağlık bakımı maliyeti
- Polat HH, Öncel S, Turhan S, Akcan A, Eravşar K, Yalçın N. Influenza vaccination in 65 and over age adults in Antalya/Turkey. Turkish Journal of Geriatrics. 2012;15(4):371-7. [Link]
- TÜİK, (2012a), Türkiye'nin Demografik Yapısı ve Geleceği, 2010-2050, News Bulletin.
- World Health Organization. Global vaccine action plan. Global Vaccine Action Plan 2011-2020. USA: WHO; 2013. p.9-21. [Link]
- TÜİK [İnternet]. [Erişim tarihi: 05 Ekim 2020]. İstatistiklerle Yaşlılar, 2019. Erişim linki: [Link]
- Atsız Sezik H, Tekin N. Knowledge, attitudes and behaviours of elderly people living at a nursing home related to pneumococcal and influenza vaccines. Turkish Journal of Geriatrics. 2021;24(2):264-75. [Crossref]
- Fedson DS. Pneumococcal vaccination: four issues for western Europe. Biologicals. 1997;25(2):215-9. [Crossref] [PubMed]
- Lang PO, Aspinall R. Vaccination in the elderly: what can be recommended? Drugs Aging. 2014;31(8):581-99. [Crossref] [PubMed]
- Atkinson W, Wolfe S, Hamborsky J. Pneumococcal Disease. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed. Washington DC: Public Healt Foundation; 2012. p.233-48.
- Immunization Work Group of the National and Global Public Health Committee of the Infectious Diseases Society of America. Actions to strengthen adult and adolescent immunization coverage in the United States: policy principles of the Infectious Diseases Society of America. Clin Infect Dis. 2007;44(12):e104-8. [Crossref] [PubMed]
- Hekimoğlu CH, Emek M, Avcı E, Topal S, Demiröz M, Ergör G. Seasonal influenza vaccine effectiveness in preventing laboratory confirmed influenza in 2014-2015 season in Turkey: a test-negative case control study. Balkan Med J. 2018;35(1):77-83. [Crossref] [PubMed] [PMC]
- Ament A, Baltussen R, Duru G, Rigaud-Bully C, de Graeve D, Ortqvist A, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis. 2000;31(2):444-50. [Crossref] [PubMed]
- Turkey Infectious Diseases and Clinical Microbiology Specialist Association. Adult immunization guide. Erişim tarihi: 14.03.2022. Available at: [Link]
- Hedlund J, Christenson B, Lundbergh P, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine. 2003;21(25-26):3906-11. [Crossref] [PubMed]
- Sütlü S. 65 yaş üstü erişkinlerde aşı uygulamaları [Vaccination applications in adults over 65 years old]. Curr Perspect Health Sci. 2022;3(1):39-44. [Link]
- Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995;123(7):518-27. [Crossref] [PubMed]
- Hamborsk J, Kroger A, Wolfe S. Epidemiology and Prevention of Vaccine-Preventable Diseases. Washington: Public Health Foundation; 2017; 3(1):39-44.
- Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, et al; EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis. 2006;43(7):860-8. [Crossref] [PubMed]
- Chan Carusone SB, Walter SD, Brazil K, Loeb MB. Pneumonia and lower respiratory infections in nursing home residents: predictors of hospitalization and mortality. J Am Geriatr Soc. 2007;55(3):414-9. [Crossref] [PubMed]
- Vural R, Yazıcı S, Özen M, Kurşun H. Antalya'da bir kliniğe başvuran 60 yaş ve üzeri bireylerin aşılanma durumları [The vaccination status among the individuals aged 60 years and older admitted to a clinic in Antalya]. STED. 2016;25(2):62-9. [Link]
- Bülbül Y, Öztuna F, Gülsoy A, Özlü T. Doğu Karadeniz Bölgesinde kronik obstrüktif akciğer hastalığı: hastalık özellikleri ve influenza-pnömokok aşılama sıklığı [Chronic obstructive pulmonary disease in eastern black sea region: characteristics of the disease and the frequency of influenza-pneumococcal vaccination]. J Med Sci. 2010;30(1):24-9. [Crossref]
- Aka Aktürk Ü, Görek Dilektaşlı A, Şengül A, Musaffa Salepçi B, Oktay N, Düger M, et al. Influenza and pneumonia vaccination rates and factors affecting vaccination among patients with chronic obstructive pulmonary disease. Balkan Med J. 2017;34(3):206-11. [Crossref] [PubMed] [PMC]
- İnal MT, Memiş D, Yelken BB, Süt N. Intensive care cost analysis of patients with acute exacerbations of chronic obstructive pulmonary diseases from two university hospitals. Trakya Univ Tip Fak Derg. 2010;27(4):391-4. [Link]
- Erdoğdu HI, Çatak B. Influenza, pneumococcal and herpes zoster vaccination rates amongst people aged 65 years and older and related factors. Turkish Journal of Geriatrics. 2018;21(4):498-506. [Crossref]
- Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348(14):1322-32. [Crossref] [PubMed]
- Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis. 2006;42(8):1093-101. [Crossref] [PubMed]
- Ryan J, Zoellner Y, Gradl B, Palache B, Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine. 2006;24(47-48):6812-22. [Crossref] [PubMed]
- Seki M. Strategies for geriatric pneumonia in healthcare facilities - how effective is combined influenza and pneumococcal vaccination? Int J Gen Med. 2020;13:663-6. [Crossref] [PubMed] [PMC]
.: Process List